New US product launch, VENXXIVA™ (tiopronin) Delayed-Release Tablets for the treatment of cystinuria Original Story BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals Limited (Cycle) announced today the launch of VENXXIVA (tiopronin) Delayed-Release Tablets, for the treatment of cystinuria, approved by the US Food and Drug Administration (FDA).1 VENXXIVA is launched in partnership between Cycle and Torrent Pharma Inc. (Torrent), and [...]

Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria Original Story PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, provides an update on recent exchanges with [...]

Cystinuria-Related Urinary Stone as the Cause of Repeated Urinary Tract Infections (UTIs) in a Child Original Story Abstract Urinary tract infections (UTIs) are one of the most common bacterial infections in children and are associated with both acute and long-term complications. Most UTIs typically resolve after antibiotic treatment. However, UTIs may be the initial clinical [...]

EAU Updates Urinary Stone Guidelines Original Story The European Association of Urology (EAU) has updated its urolithiasis guidelines to  reflect scientific evidence that has emerged during the last 8 years. The panel of experts who wrote the updated guidelines reviewed them in a European Urology article that addresses which patients are at high risk for stone recurrence, [...]

Challenges in diagnosis and treatment of cystinuria patients with Urolithiasis: multicenter patient centered study. Original Story Cystinuria represents a rare cause of urolithiasis, accounting for 1% of all cases. However, it poses unique challenges in diagnosis and management. This study aimed to examine the challenges of managing cystine stones from the perspective of cystinuria patients. [...]

Cystinuria drugs in development, 2024 Original Story The Cystinuria drugs in development market research report provides comprehensive information on the therapeutics under development for Cystinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs [...]

Cable jointers ascend Snowdon to raise £2K for children’s hospital London News Online Original Story  Cable jointers ascend Snowdon to raise £2K for children’s hospital 31 July 2024Claudia Lee Nine cable jointers and craft attendants from UK Power Networks ascended Mount Snowdon in a bid to raise funds for a children’s hospital. The group raised [...]

HÜDA PAR submits parliamentary question on cystinuria medication supply HÜDA PAR Batman MP Serkan Ramanlı has submitted a parliamentary question to the Grand National Assembly of Turkey, addressing the difficulties cystinuria patients face in obtaining essential medication. In a formal question submitted to the Parliament Speaker’s Office, Ramanlı requested Health Minister Kemal Memişoğlu to provide [...]

Endo Launches Tiopronin Delayed-Release Tablets, Generic Version of THIOLA EC® MALVERN, Pa. , July 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of tiopronin delayed-release tablets, a generic version of Travere Therapeutics' THIOLA EC ® . "We're proud to provide high-quality, affordable choices to healthcare providers and their appropriate patients," said Scott [...]